KEY POINTS
- FEMINICOL (NCT03956498) was a prospective, single-center study conducted at IUCT-Oncopole, Toulouse, France, evaluating structured sexological follow-up in women undergoing definitive chemoradiotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer. Between October 2019 and December 2020, 60 patients were enrolled, of whom 56 had evaluable longitudinal data. Median age was 54.5 years (range 31–77), and 58.5% of patients with available staging information had FIGO 2018 stage IIIC disease. The cohort received external-beam radiotherapy, generally 45 Gy in 25 fractions, with concurrent weekly cisplatin in most patients, followed by pulse-dose-rate intracavitary brachytherapy, with interstitial needles when indicated.
- Sexological follow-up was systematically integrated into the treatment pathway. Patients met a certified sexological nurse before brachytherapy, approximately two months after treatment, and again at one year. Counseling addressed sexual function, body image, fear of pain or bleeding, communication with partners, and vaginal rehabilitation. Each patient received a set of vaginal dilators and instructions to perform dilation twice weekly, with reduced frequency permitted for women having regular sexual intercourse. Adherence was assessed pragmatically as dilator use at least once weekly and/or frequent sexual intercourse. Attendance at sexological consultations reached 98.1% (53/54) at two months and 100% (47/47) among patients attending one-year clinical follow-up.
- Sexual function improved significantly over the observation period, although it remained substantially impaired at one year. Median Female Sexual Function Index (FSFI) score increased from 4.0 after chemoradiotherapy but before brachytherapy to 10.3 at two months and 12.5 at one year. Among 43 patients with paired baseline and one-year FSFI assessments, mean improvement was 9.1 points (95% CI 5.3–12.8), with a median paired change of +6.7 points (p<0.001). Importantly, the baseline assessment was performed after completion of external-beam chemoradiotherapy, not before cancer treatment, and improvement from this markedly impaired baseline does not demonstrate recovery of premorbid sexual function.
- Reported sexual activity and overall quality of life also improved, but sexual anxiety persisted. At one year, 45.7% of patients (21/46 with available sexual activity data) reported being sexually active. Median EORTC QLQ-CX24 sexual activity score increased from 0 to 33.3 (p<0.001), while median EORTC QLQ-C30 global health status increased from 50.0 at baseline to 75.0 at one year (p<0.001). However, paired sexual anxiety scores showed no significant improvement (p=0.932), with 75.7% of evaluable patients reporting stable or worsening anxiety. These findings suggest that functional recovery and psychological adjustment may follow different trajectories.
- Adherence to vaginal rehabilitation decreased over time despite systematic support. At two months, 41/53 patients (77.4%) met the rehabilitation adherence definition, declining to 26/47 (55.3%) at one year. Patients who remained adherent had a significantly greater improvement in FSFI score than nonadherent patients (median change +16.2 vs +0.8 points; p=0.017). One-year sexual activity scores were also higher among adherent patients (median 33.3 vs 0; p=0.046). However, patients adhering to rehabilitation were more likely to have been sexually active at baseline (84.6% vs 57.1%; p=0.036), indicating potential confounding by pre-existing sexual function and motivation.
- Vaginal morbidity remained common, including clinically significant late complications. At one year, vaginal narrowing occurred in 29.8%, while vaginal stenosis and dryness each affected 40.4% of patients. Six of 47 patients (12.7%) experienced at least one grade 3 vaginal or pelvic adverse event, including grade 3 vaginal narrowing in four patients (8.5%) and grade 3 stenosis in one (2.1%). Severe vaginal toxicity was numerically less frequent among rehabilitation-adherent patients (3.8% vs 23.8%), but this difference was not statistically significant (p=0.076). Most patients reported lower-grade morbidity, and the study did not analyze detailed vaginal dose-volume parameters that could explain individual toxicity differences.
- Most respondents valued the intervention, but its independent effectiveness was not established. Among 43 patients completing the satisfaction assessment, 35 (81.4%) reported that sexological support had been beneficial for rehabilitation and adjustment. Nevertheless, FEMINICOL had no randomized or contemporaneous control group, making it impossible to distinguish effects of counseling from natural recovery, patient motivation, partner support, or other clinical factors. The small cohort, attrition during follow-up, missing questionnaire data, and absence of detailed vaginal dosimetry further limit interpretation. The observed improvement in sexual function therefore cannot be attributed causally to the rehabilitation program.
CLINICAL TAKEAWAY
Structured sexological follow-up during and after definitive cervical cancer chemoradiotherapy and brachytherapy was feasible and accompanied by improved patient-reported sexual function and continued vaginal rehabilitation in approximately half of patients at one year. However, severe vaginal morbidity remained clinically relevant, and sexual anxiety showed no significant improvement. The absence of a control group prevents conclusions about the intervention's independent effectiveness, supporting further prospective evaluation of individualized sexual rehabilitation and psychological care.